- Introduced
- In committeeEnergy and Commerce
- Passed the House (not yet)
- Passed the Senate (not yet)
- Law (not yet)
What it says
About this text
Text: Introduced The text as a member of Congress first filed it. Most bills never get further than this., (the only version so far)
This bill creates or directs, rather than amending the Code.
Its own words follow, as Congress.gov publishes them.
Sec. 1. Nullification of modifications to REMS for mifepristone
(a) Nullification The modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for mifepristone are hereby nullified.
(b) No substantially similar provisions The Secretary of Health and Human Services (or any head of any office, department, or agency of the Department of Health and Human Services) shall not establish, implement, or enforce any provision of a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for mifepristone that is substantially similar to any of the modifications nullified by subsection (a).